|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
in00003502241 |
| 005 |
20190407120204.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
040318s2004 njua ob 001 0 eng d |
| 019 |
|
|
|a 606412401
|a 607063361
|
| 020 |
|
|
|a 1592597394 (electronic bk.)
|
| 020 |
|
|
|a 9781592597390 (electronic bk.)
|
| 020 |
|
|
|z 1588292282 (alk. paper)
|
| 020 |
|
|
|z 9781588292285 (alk. paper)
|
| 035 |
|
|
|a (OCoLC)ocm54760446
|
| 035 |
|
|
|a (OCoLC)54760446
|z (OCoLC)606412401
|z (OCoLC)607063361
|
| 040 |
|
|
|a N$T
|b eng
|c N$T
|d OCLCQ
|d YDXCP
|d OCLCG
|d OCLCQ
|d OCLCE
|d E7B
|d OCLCQ
|d OCLCO
|d GW5XE
|d OCLCF
|d UtOrBLW
|
| 042 |
|
|
|a dlr
|
| 049 |
|
|
|a TXAM
|
| 050 |
|
4 |
|a RC271.C5
|b A6722 2004eb
|
| 060 |
|
4 |
|a QV 269
|b A62953 2004
|
| 072 |
|
7 |
|a MED
|x 062000
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 039030
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99/4061
|2 22
|
| 245 |
0 |
0 |
|a Anticancer drug development guide :
|b preclinical screening, clinical trials, and approval /
|c edited by Beverly A. Teicher, Paul A. Andrews.
|
| 250 |
|
|
|a 2nd ed.
|
| 264 |
|
1 |
|a Totowa, N.J. :
|b Humana Press,
|c [2004]
|
| 264 |
|
4 |
|c ©2004
|
| 300 |
|
|
|a 1 online resource (xiv, 450 pages) :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer drug discovery and development
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a High-volume screening / Michel Pagä -- High-throughput screening in industry / Michael D. Boisclair ... [et al.] -- The NCI human tumor cell line (60-cell) screen: concept, implementation, and applications / Michael R. Boyd -- Human tumor screening / Axel-R. Hanauske, Susan G. Hilsenbeck, and Daniel D. Von Hoff -- Murine L1210 and P388 leukemias / William R. Waud -- In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery / Thomas Corbett ... [et al.] -- Human tumor xenograft models in NCI drug development / Michael C. Alley ... [et al.] -- Specialized in vitro/in vivo procedures employed by the NCI in preclinical drug evaluations / Melinda G. Hollingshead ... [et al.].
|
| 505 |
0 |
|
|a Patient-like orthotopic metastatic models of human cancer / Robert M. Hoffman -- Preclinical models for combination therapy / Beverly A. Teicher -- Models for biomarkers and minimal residual tumor / Beverly A. Teicher -- Spontaneously occurring tumors in companion animals as models for drug development / David M. Vail and Douglas H. Thamm -- Nonclinical testing: from theory to practice / Denis Roy and Paul A. Andrews -- Nonclinical testing for oncology drug products / Paul A. Andrews and Denis Roy -- Nonclinical testing for oncology biologic products / Carolyn M. Laurenìot, Denis Roy, and Paul A. Andrews.
|
| 505 |
0 |
|
|a Working with the national cancer institute / Paul Thambi and Edward A. Sausville -- Phase I trial design and methodology for anticancer drugs / Patrick V. Acevedo, Deborah L. Toppmeyer, and Eric H. Rubin -- Phase II trials: conventional design and novel strategies in the era of targeted therapies / Keith T. Flaherty and Peter J. O'Dwyer.
|
| 505 |
0 |
|
|a Drug development in Europe: the academic perspective / Chris Twelves ... [et al.] -- The phase III clinical cancer trial / Ramzi N. Dagher and Richard Pazdur -- Assessing tumor-related symptoms and health-related quality of life in cancer clinical trials: a regulatory perspective / Judy H. Chiao, Grant Williams, and Donna Griebel -- The role of the oncology drug advisory committee in the FDA review process for oncologic products / Leslie A. Vaccari -- FDA role in cancer drug development and requirements for approval / Susan Flamm Honig.
|
| 588 |
|
|
|a Description based on print version record.
|
| 520 |
|
|
|a In this thoroughly updated and expanded second edition of Beverly Teicher's widely used classic survey, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, leading cancer researchers from pharmaceutical companies, government laboratories, and academia provide a step-by-step guide to anticancer drug development from initial design through FDA approval. The authors have included new material on the use of high-throughput screening in industry, on specialized in vitro/in vivo procedures employed by the National Cancer Institute (NCI) in preclinical drug evaluations, and on nonclinical testing to support both human clinical trials, as well as trials of biologic oncology products. There are also new chapters on health-related quality of life (HRQL) issues in cancer clinical trials, and FDA review and requirements for approval of oncologic products. The chapters on phase I, II, and III clinical trials and on novel phase II clinical trial designs for targeted therapies have been significantly updated, along with those on cancer drug development in Europe, on working with the NCI, as well as on the FDA's role in cancer drug development and in setting requirements for approval. Authoritative and up-to-date, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval takes oncologists, pharmacologists, medicinal chemists, and other cancer researchers on an encyclopedic tour of the cancer drug development and approval process, moving from the design and execution of high-throughput screens, to preclinical testing, to safety and toxicity testing under FDA requirements, to early clinical trials, and on to final FDA approval.
|
| 538 |
|
|
|a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
|u http://purl.oclc.org/DLF/benchrepro0212
|5 MiAaHDL
|
| 583 |
1 |
|
|a digitized
|c 2010
|h HathiTrust Digital Library
|l committed to preserve
|2 pda
|5 MiAaHDL
|
| 500 |
|
|
|a Electronic resource.
|
| 650 |
|
0 |
|a Antineoplastic agents
|x Development.
|
| 650 |
1 |
2 |
|a Antineoplastic Agents
|x standards.
|
| 650 |
2 |
2 |
|a Clinical Trials as Topic.
|
| 650 |
2 |
2 |
|a Drug Approval.
|
| 650 |
2 |
2 |
|a Drug Design.
|
| 650 |
2 |
2 |
|a Drug Evaluation, Preclinical.
|
| 650 |
|
6 |
|a Anticancéreux
|x Développement.
|
| 650 |
|
7 |
|a MEDICAL
|x Oncology.
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Cancer.
|2 bisacsh
|
| 650 |
|
7 |
|a Antineoplastic agents
|x Development.
|2 fast
|0 (OCoLC)fst00810599
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Teicher, Beverly A.,
|d 1952-
|
| 700 |
1 |
|
|a Andrews, Paul A.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 776 |
1 |
8 |
|i Print version:
|t Anticancer drug development guide.
|b 2nd ed.
|d Totowa, N.J. : Humana Press, c2004
|z 1588292282
|w (DLC) 2003024925
|w (OCoLC)53443077
|
| 830 |
|
0 |
|a Cancer drug discovery and development.
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=http://link.springer.com/10.1007/978-1-59259-739-0
|z Connect to the full text of this electronic book
|t 0
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
|
|
|a MARS
|
| 999 |
f |
f |
|s 9c365702-8f4f-316f-9561-c93274951367
|i 0054d4a5-ea19-384a-b664-4de39133f228
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|d Available Online
|t 0
|e RC271.C5 A6722 2004eb
|h Library of Congress classification
|
| 998 |
f |
f |
|a RC271.C5 A6722 2004eb
|t 0
|l Available Online
|